What Happened
On October 15, 2026, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending that the European Union grant a marketing authorization for Foundayo (orforglipron), Eli Lilly's oral GLP-1 receptor agonist — for both weight management and type 2 diabetes in adults.
The opinion moves Europe one step from its second approved GLP-1 pill, and its first built on small-molecule chemistry. Orforglipron is not a peptide: it is a synthetic small molecule that activates the GLP-1 receptor, which is why it can be taken as a simple tablet rather than an injection. The recommendation now passes to the European Commission, which normally issues its final decision within 67 days of the opinion.
If the Commission confirms the opinion, Foundayo would become the first oral GLP-1 medicine authorized in the EU for diabetes as well as weight management — Novo Nordisk's oral semaglutide product is licensed in Europe for weight management alone. We covered the molecule's US approval and access implications in our earlier analysis.
Who Is Affected
- Adults with obesity (initial BMI of 30 or higher), or overweight (BMI 27 to under 30) with at least one weight-related comorbidity such as prediabetes, type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnea, or cardiovascular disease
- Adults with insufficiently controlled type 2 diabetes, who gain access to a new oral treatment class
- National health systems — pricing and reimbursement will be negotiated country by country after any Commission approval
- Novo Nordisk, whose oral semaglutide pill currently holds the European first-mover position
Timeline
- April 1, 2026 — The US FDA approves Foundayo, making it the first non-peptide GLP-1 medicine on any major market
- October 15, 2026 — CHMP adopts its positive opinion for EU-wide authorization
- Within ~67 days — The European Commission is expected to adopt its final decision
- Afterward — Each member state negotiates price and reimbursement independently
What This Means for Researchers
The recommendation rests on two phase 3 studies enrolling more than 4,740 adults with obesity or overweight. Over 72 weeks, participants treated with Foundayo lost roughly 5 to 11 percent of their body weight depending on the assigned treatment group, compared with about 2 to 2.5 percent for placebo. The most common side effects were gastrointestinal — nausea, vomiting, and diarrhea.
The scientific significance is chemical rather than commercial: orforglipron demonstrates that clinically meaningful GLP-1 receptor agonism does not require a peptide chain. A small molecule achieves what previously demanded injectable peptides, with no reconstitution, no cold-chain vials, and no injection-device logistics. For bench researchers, that raises new comparative questions — receptor selectivity, duration of action, and how a non-peptide agonist performs head-to-head against semaglutide and the injectable GLP-1 peptides.
How to Verify Your Peptides
Foundayo is not a peptide and has no legitimate research-supply chain, but copycat "orforglipron" listings inevitably follow every major GLP-1 approval. Independent analytical testing remains the only reliable check on mislabeled or contaminated vials:
- How peptide testing works
- HPLC vs LC-MS: which method tells you what
- Identity, purity, and fill-weight verification
Safe Alternatives
Researchers evaluating well-characterized compounds can browse our peptide reference library and our vetted vendor listings for suppliers with published third-party test results.
Sources
Regulatory announcements (EMA/CHMP summary of opinion, October 2026); industry reports.